Clear Creek Financial Management LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

Clear Creek Financial Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 23.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,168 shares of the biopharmaceutical company’s stock after selling 4,701 shares during the period. Clear Creek Financial Management LLC’s holdings in Pfizer were worth $384,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Lincoln Capital Corp lifted its stake in Pfizer by 30.5% during the 1st quarter. Lincoln Capital Corp now owns 14,720 shares of the biopharmaceutical company’s stock worth $373,000 after acquiring an additional 3,441 shares in the last quarter. Vontobel Holding Ltd. grew its position in Pfizer by 4.3% in the 1st quarter. Vontobel Holding Ltd. now owns 721,427 shares of the biopharmaceutical company’s stock valued at $18,281,000 after acquiring an additional 29,825 shares in the last quarter. Rovin Capital UT ADV increased its stake in Pfizer by 17.8% during the first quarter. Rovin Capital UT ADV now owns 28,507 shares of the biopharmaceutical company’s stock worth $722,000 after purchasing an additional 4,303 shares during the period. Mather Group LLC. lifted its position in shares of Pfizer by 9.8% during the first quarter. Mather Group LLC. now owns 22,185 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 1,978 shares in the last quarter. Finally, Alta Advisers Ltd boosted its stake in shares of Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 13,100 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.1%

Pfizer stock opened at $25.32 on Thursday. The stock has a market cap of $143.95 billion, a PE ratio of 18.35, a P/E/G ratio of 0.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock’s fifty day moving average is $23.62 and its two-hundred day moving average is $24.83. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.82 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.79%. Pfizer’s dividend payout ratio is presently 124.64%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PFE. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.